Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00264446 · ClinicalTrials.gov registry record · Phase 1
A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection
A Phase 1 study, sponsored by Adherex Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00264446: Completed Phase 1 study, sponsored by Adherex Technologies.
NCT00264446 is a Phase 1 study that has completed, run by Adherex Technologies. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00264446, a Phase 1 study, has completed, sponsored by Adherex Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
5 fluorouracil (5 FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD. This study will examine the kinetics of inhibition and recovery of the metabolic pathways for fluoropyrimidines in subjects who receive a single oral dose of ADH300004, and may allow optimization of oral 5 FU dosing to subjects in future studies.
Interventions
- DRUG ADH300004
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
What the finished NCT00264446 record still lists
NCT00264446 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which ADH300004 is the first listed.
NCT00264446 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00264446 about?
NCT00264446 is a clinical study titled "A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection". 5 fluorouracil (5 FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD. This study will examine the kinetics of inhibition and recovery of the metabolic pathways for fluoropyrimidines in subject...
What is the current status of trial NCT00264446?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00264446?
The interventions under investigation include: ADH300004 (DRUG).
Who is sponsoring clinical trial NCT00264446?
This trial is sponsored by Adherex Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.